Sort   by:  
 Page size 
UnknownNovel NPM1 exon 5 mutations and gene fusions leading to aberrant cytoplasmic nucleophosmin in AML.
Not available
S-EPMC9037756 | biostudies-literature
UnknownVenetoclax plus hypomethylating agents as effective bridge therapy to allogeneic stem cell transplant in relapsed/refractory acute myeloid leukaemia: A subanalysis of the AVALON study
Not available
S-EPMC12916181 | biostudies-literature
UnknownImpact of Pre-Treatment Comorbidity Burden on Survival in Patients Receiving Venetoclax Plus Hypomethylating Agents.
Not available
S-EPMC11886493 | biostudies-literature
UnknownReal-world multicenter analysis of CPX-351 efficacy in patients aged less than 60 years with secondary acute myeloid leukemia.
Not available
S-EPMC12554896 | biostudies-literature
UnknownMolecular mechanisms generating and stabilizing terminal 22q13 deletions in 44 subjects with Phelan/McDermid syndrome.
Not available
S-EPMC3136441 | biostudies-literature
UnknownImpact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351∗
Not available
S-EPMC12915183 | biostudies-literature
UnknownReal World Study on the Best CPX-351 Treatment Duration and Timing for Allogeneic Stem Cell Transplantation.
Not available
S-EPMC12603885 | biostudies-literature
UnknownBi-allelic ACBD6 variants lead to a neurodevelopmental syndrome with progressive and complex movement disorders.
Not available
S-EPMC10994533 | biostudies-literature
UnknownExome sequencing of 20,979 individuals with epilepsy reveals shared and distinct ultra-rare genetic risk across disorder subtypes.
Not available
S-EPMC11646479 | biostudies-literature
Sort   by:  
 Page size